Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2015—Thermo Fisher Scientific has released a next-generation sequencing RNA panel and workflow that enables targeted sequencing of fusion transcripts for clinical research. The Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel allows simultaneous sequencing of 70 ALK, RET, ROS1, and NTRK1 fusion transcripts associated with lung cancer as well as 5’ and 3’ ALK gene expression.
March 2015—The CE-IVD Oncomine Solid Tumor DNA kit from Thermo Fisher Scientific enables accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor. Based on the Ion Torrent AmpliSeq technology, the kit allows detection of single nucleotide somatic changes, inversions, insertions, and deletions using as little as 10 ng of FFPE DNA …
February 2014—Thermo Fisher Scientific has signed an agreement with Cynvenio Biosystems, a molecular testing company focused on the genomic analysis of tumor biomarkers in the bloodstream, for rights to distribute its LiquidBiopsy platform. The automated LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a standard blood draw in preparation for high-content imaging and genomic analysis.
January 2015—Thermo Fisher Scientific launched its DRI Hydrocodone/Hydromorphone Assay, a homogeneous enzyme immunoassay that specifically detects hydrocodone and major metabolites in human urine at a 300 ng/mL cut-off. The assay uses liquid ready-to-use reagents, calibrators, and controls and can be run in qualitative and semiquantitative modes.
December 2014—Laboratories performing food and environmental testing, clinical research, forensic toxicology, pharmaceutical or biopharmaceutical measurements, and other applied analyses can now benefit from the performance of high-resolution accurate-mass (HRAM) Orbitrap mass spectrometry using an instrument designed for cost-per-sample-sensitive workflows.
December 2014—The Thermo Scientific XBF40 series of -40°C blast freezers are for rapid cooling during the sample preparation process, prior to freezer storage. Available in two options, the XBF40D-MD is designed for rapid plasma freezing and accommodates plasma bags, boxes, and bottles, and the XBF40D is for general-purpose applications and accommodates staggered loads and a variety of vessels, such as carboys, bottles, racks with vials, and more.
December 2014—Thermo Fisher Scientific announced the successful CE-IVD registration of its Ion PGM Dx System for sale in European countries. The system was developed using the Ion Torrent next-generation sequencing technology, currently used in clinical research laboratories to produce tests to uncover meaningful genetic information for a range of human conditions.
November 2014—Clinical laboratories running next-generation sequencing oncology tests now have access to a universal quality control material compatible with multiple sequencing platforms. The AcroMetrix Oncology Hotspot Control from Thermo Fisher Scientific provides a common quality control material that can be used in laboratories with different NGS instrument platforms, assays, and bioinformatics pipelines to test precision and detect analytical deviations that may arise from reagent and instrument variation.
October 2014—Thermo Fisher Scientific announced it has completed the sale of its Cole-Parmer customer channel business to private equity firm GTCR for approximately $480 million in cash.
August 2014—E1-ClipTip electronic pipettes from Thermo Fisher Scientific are designed to maintain precise sample volumes on every channel with fewer repetitions and reproducible results for multiple application types. The ClipTip technology, electronic tip ejection, intuitive personalized user interface, and adjustable tip spacing for sample transfers make the E1-ClipTip pipette an optimal solution for complex and demanding protocols.
